These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 9215602)

  • 1. Fostriecin: a review of the preclinical data.
    de Jong RS; de Vries EG; Mulder NH
    Anticancer Drugs; 1997 Jun; 8(5):413-8. PubMed ID: 9215602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fostriecin-mediated G2-M-phase growth arrest correlates with abnormal centrosome replication, the formation of aberrant mitotic spindles, and the inhibition of serine/threonine protein phosphatase activity.
    Cheng A; Balczon R; Zuo Z; Koons JS; Walsh AH; Honkanen RE
    Cancer Res; 1998 Aug; 58(16):3611-9. PubMed ID: 9721869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor drug fostriecin inhibits the mitotic entry checkpoint and protein phosphatases 1 and 2A.
    Roberge M; Tudan C; Hung SM; Harder KW; Jirik FR; Anderson H
    Cancer Res; 1994 Dec; 54(23):6115-21. PubMed ID: 7954457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance.
    de Jong S; Zijlstra JG; Mulder NH; de Vries EG
    Cancer Chemother Pharmacol; 1991; 28(6):461-4. PubMed ID: 1657425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin.
    de Jong RS; Mulder NH; Uges DR; Sleijfer DT; Höppener FJ; Groen HJ; Willemse PH; van der Graaf WT; de Vries EG
    Br J Cancer; 1999 Feb; 79(5-6):882-7. PubMed ID: 10070885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor antibiotic fostriecin covalently binds to cysteine-269 residue of protein phosphatase 2A catalytic subunit in mammalian cells.
    Takeuchi T; Takahashi N; Ishi K; Kusayanagi T; Kuramochi K; Sugawara F
    Bioorg Med Chem; 2009 Dec; 17(23):8113-22. PubMed ID: 19857968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of DNA topoisomerase II inhibitors on human bone marrow progenitor cells.
    Francis GE; Tejedor MC; Berney JJ; Chresta CM; Delgado C; Patel P
    Leukemia; 1994 Jan; 8(1):121-8. PubMed ID: 8289477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Catalyst-controlled asymmetric synthesis of fostriecin and 8-epi-fostriecin.
    Maki K; Motoki R; Fujii K; Kanai M; Kobayashi T; Tamura S; Shibasaki M
    J Am Chem Soc; 2005 Dec; 127(48):17111-7. PubMed ID: 16316259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of type II topoisomerase by fostriecin.
    Boritzki TJ; Wolfard TS; Besserer JA; Jackson RC; Fry DW
    Biochem Pharmacol; 1988 Nov; 37(21):4063-8. PubMed ID: 2847752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The antitumor drug fostriecin induces vimentin hyperphosphorylation and intermediate filament reorganization.
    Ho DT; Roberge M
    Carcinogenesis; 1996 May; 17(5):967-72. PubMed ID: 8640945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fostriecin, an antitumor antibiotic with inhibitory activity against serine/threonine protein phosphatases types 1 (PP1) and 2A (PP2A), is highly selective for PP2A.
    Walsh AH; Cheng A; Honkanen RE
    FEBS Lett; 1997 Oct; 416(3):230-4. PubMed ID: 9373158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response of murine small intestine to combined treatment with fostriecin and X rays.
    Rao KR; Fritz-Niggli H
    Br J Radiol; 1990 Apr; 63(748):286-9. PubMed ID: 2346866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total synthesis of an antitumor antibiotic, Fostriecin (CI-920).
    Miyashita K; Ikejiri M; Kawasaki H; Maemura S; Imanishi T
    J Am Chem Soc; 2003 Jul; 125(27):8238-43. PubMed ID: 12837094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fostriecin: chemistry and biology.
    Lewy DS; Gauss CM; Soenen DR; Boger DL
    Curr Med Chem; 2002 Nov; 9(22):2005-32. PubMed ID: 12369868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitor.
    Hajji N; Mateos S; Pastor N; Domínguez I; Cortés F
    Mutat Res; 2005 May; 583(1):26-35. PubMed ID: 15866463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical toxicological evaluation of fostriecin, a novel anticancer antibiotic, in rats.
    Susick RL; Hawkins KL; Pegg DG
    Fundam Appl Toxicol; 1990 Aug; 15(2):258-69. PubMed ID: 2227154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA topoisomerase I content of a pair of human melanoma cell lines with very different radiosensitivities correlates with their in vitro sensitivities to camptothecin.
    Ng CE; Cybulski SE; Bussey AM; Aubin RA; Raaphorst GP
    Anticancer Res; 1998; 18(4C):3119-26. PubMed ID: 9713520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of fostriecin pharmacokinetics in plasma using high-pressure liquid chromatography assay.
    Pillon L; Moore MJ; Thiessen JJ
    Ther Drug Monit; 1994 Apr; 16(2):186-90. PubMed ID: 8009568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total synthesis of fostriecin (CI-920).
    Boger DL; Ichikawa S; Zhong W
    J Am Chem Soc; 2001 May; 123(18):4161-7. PubMed ID: 11457179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of topoisomerase poisoning by antitumor drugs VM 26, fostriecin and camptothecin on DNA repair replication by mammalian cell extracts.
    Frosina G; Rossi O
    Carcinogenesis; 1992 Aug; 13(8):1371-7. PubMed ID: 1323426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.